

1625 JFW

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>FEE TRANSMITTAL</b> <b>for FY 2005</b> <i>Effective 10/01/2004. Patent fees are subject to annual revision.</i>		<b>Complete if Known</b>		
		Application Number	09/839,424	
		Filing Date	April 20, 2001	
		First Named Inventor	David L. Brown	
		Examiner Name	Binta M. Robinson	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Art Unit	1625	
TOTAL AMOUNT OF PAYMENT (\$)		\$110.00	Attorney Docket No.	3364/1/US

<b>METHOD OF PAYMENT</b> (check all that apply)		<b>FEE CALCULATION</b> (continued)			
<input type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None		<b>3. ADDITIONAL FEES</b>			
<input checked="" type="checkbox"/> Deposit Account:		<b>Large Entity</b> <b>Small Entity</b>			
Deposit Account Number: 19-1025		Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
Deposit Account Name: Pharmacia Corporation		1051 130	2051 65	Surcharge - late filing fee or oath	
The Director is authorized to: (check all that apply)		1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
<input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments		1053 130	1053 130	Non - English specification	
<input checked="" type="checkbox"/> Charge any additional fee(s) or any underpayment of fee(s)		1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.		1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
		1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
		1251 110	2251 55	Extension for reply within first month	
		1252 430	2252 215	Extension for reply within second month	
		1253 980	2253 490	Extension for reply within third month	
		1254 1,530	2254 765	Extension for reply within fourth month	
		1255 2,080	2255 1,040	Extension for reply within fifth month	
		1401 340	2401 170	Notice of Appeal	
		1402 340	2402 170	Filing a brief in support of an appeal	
		1403 300	2403 150	Request for oral hearing	
		1451 1,510	1451 1,510	Petition to institute a public use proceeding	
		1452 110	2452 55	Petition to revive - unavoidable	
		1453 1,370	2453 685	Petition to revive - unintentional	
		1501 1,370	2501 685	Utility issue fee (or reissue)	
		1502 490	2502 245	Design issue fee	
		1503 660	2503 330	Plant issue fee	
		1460 130	1460 130	Petitions to the Commissioner	
		1807 50	1807 50	Processing fee under 37 CFR § 1.17(q)	
		1806 180	1806 180	Submission of Information Disclosure Statement	
		8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
		1809 790	2809 395	Filing a submission after final rejection (37 CFR § 1.129(a))	
		1810 790	2810 395	For each additional invention to be examined (37 CFR § 1.129(b))	
		1801 790	2801 395	Request for Continued Examination (RCE)	
		1802 900	1802 900	Request for expedited examination of a design application	
		Other fee (specify) <u>Statutory Disclaimer</u>			110.00
		SUBTOTAL (3) (\$)			\$110.00

<b>SUBMITTED BY</b>		<b>Complete (if applicable)</b>			
Name (Print/Type)	Philip B. Polster, II	Registration No. (Attorney/Agent)	43,864	Telephone	314.274.9094
Signature		Date	November 22, 2004		

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**TERMINAL DISCLAIMER TO OBTAIN A PROVISIONAL DOUBLE  
PATENTING REJECTION OVER A PENDING SECOND APPLICATION**

Docket No.


3364/1/US

In re Application of: **David L. Brown et al.**

Application No. **09/839,424**

Filed: **April 20, 2001**

For: **2-FLUOROBENZENSULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION**



The owner, Pharmacia Corporation of 100.00 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 60/199533 and 60/253380, filed on 04/25/2000 and 11/27/2000. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney of record.
3. Owner/applicant is ☐ Small entity ☒ Large entity

The terminal disclaimer fee under 37 CFR 1.20(d) is \$110.00 and is to be paid as follows:

- ☐ A check in the amount of the fee is enclosed.
- ☒ The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 19-1025.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

PTO suggested wording for terminal disclaimer was

- ☒ unchanged. ☐ changed (if changed, an explanation should be supplied.)

  
Signature

Name and Address of Person Signing

Philip B. Polster II, Reg. No. 43,864

Pharmacia Corporation of Pfizer Inc.

P.O. Box 1027

Chesterfield, Missouri 63006

314.274.9094

11/29/2004 YPOLITE1 00000045 191025 09839424

01 FC:1814

110.00 DA

Dated: November 22, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

November 22, 2004

(Date)

  
Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence